These microRNAs are to be added to Rosetta’s microRNA database, providing the company with additional biomarker candidates for its diagnostic development programs.
Under the terms of the agreement, Rosetta will pay an initiation fee to Rockefeller University as well as maintenance fees and royalties. More specific financial terms of the agreement were not disclosed.
“This agreement positions us to apply our experience and expand our development program further in the years ahead. We are now positioned to target a broader range of promising development and commercial opportunities in the microRNA arena,” said Amir Avniel, president and CEO of Rosetta Genomics.
Rosetta Genomics has developed a discovery process that has led to the discovery of nearly 360 biologically validated human microRNAs. The agreement with Rockefeller positions Rosetta Genomics to pursue research based on 530 of the 660 publicly-confirmed microRNA genes in the entire human genome.